CBD /

 

Loading...
Country's Decision or any other Communication (DEC)
  |  
BCH-DEC-BR-109757-1   |   PDF   |   Print   |  
| 
|  Close
last updated: 29 Feb 2016
Amendment
No
General Information
Brazil
Commercial Release: Conclusive Technical Approach for the production, marketing, and export of the product named VAXXITEK MD/IBD
EN
04 May 2004
No
Subject of the decision, notification, communication or declaration
  • Decision on Pharmaceuticals (Article 5)
LMO identification & risk assessment
  • BCH-LMO-SCBD-109735-1 Living Modified Organism VAXXITEK® HVT+ IBD
    Merial Saúde Animal Ltda(Merial) | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-RA-BR-109754-1 Risk Assessment generated by a regulatory process Risk assessment for  production, marketing, and export of the product named VAXXITEK MD/IBD
    VAXXITEK® HVT+ IBD | Turkey herpesvirus, Meleagrid herpesvirus 1, Production of medical or pharmaceutical compounds (human or animal)
Document on the decision, communication, notification or declaration

Quick links

About the BCH About the Cartagena Protocol Supplementary Protocol

Sign in Search records Submit records
Registries: LMO-Organism-Gene Country Profiles
National Report Analyzer

Forums BCH Announcements

Need help?

Knowledge Base FAQs UNEP eLearning Training Site

Contact us at: bch@cbd.int
BCH Biosafety Clearing-House
Subscribe to e-mail notifications
Subscribe to our newsletter